Company news
PreveCeutical Medical Inc news in 2023
PreveCeutical Medical Inc's news releases, calls and decks from 2023, newest first.
PreveCeutical Files Two Family Patents of Sol-Gel Cannabinoid Formulation and Antiviral Use & Cyclic Peptides and Uses Thereof
June 28, 2023
PreveCeutical Medical - Sol-Gel and Uses thereof Patent Update
May 30, 2023
PreveCeutical Medical Launches Clinical Artificial Intelligence Division
April 24, 2023
PreveCeutical Medical Announces Live Interactive Q&A Video Conference
April 20, 2023
PreveCeutical Medical Announces Frontiers Media SA Publication Featuring Data from its Analgesic Program for the Treatment of Peptide-based Therapeutics for Moderate to Severe Pain
April 4, 2023
PreveCeutical Initiates Non-Analgesic (Painkiller) Program, Clinical Development Program & Disclosure Committee
March 20, 2023
PreveCeutical - International Filing of Thermoresponsive Sol-Gels Containing Cannabinoids & Uses Thereof
March 6, 2023
Appointment of C. Evan Ballantyne to PreveCeutical's Board of Directors
February 21, 2023
PreveCeutical Awards ICON Analgesic Program (Painkiller) Clinical Development
February 7, 2023
PreveCeutical - Australian Patent Granted for Disulfide Bond Containing Compounds
January 25, 2023
PreveCeutical - Background IP, US Patent Granted Disulfide Bond Containing Compounds
January 23, 2023
PreveCeutical - Dynorphin Peptides (Painkiller) and Uses Thereof Patent Update and Officer Update
January 17, 2023
PreveCeutical Enters into License Option Agreement with Endosane Pharmaceuticals
January 12, 2023
PreveCeutical Signs Intercompany Sol-Gel License Agreement
January 9, 2023